01 nov: Lars Rasmussen fratræder sin stilling som administrerende direktø..
01 nov: Coloplast leverer et solidt årsregnskab og 8% vækst for sjette kv..
01-11-2018 08:31:40

Announcement no. 9/2018 - Full-year Financial Results 2017/18

Relateret indhold
11 jan - 
Fredagens aktier: Ambu endte i toppen i svagt negativt ..
11 jan - 
Aktier/middag: Danske Bank klarer skærene i afdæmpet ma..
11 jan - 
Aktier/åbning: William Demant topper i grøn fredagsstar..
Relateret debat
29 dec - 
@nohope Der har vaeret tale om to former for afstemning..
29 dec - 
En oldefar der i en periode har været medlem af DNSAP e..
29 dec - 
@tommycarstensen Tak for dine svar. Jeg har arbejdet me..

2017/18

Announcement of full-year financial results 2017/18

(01 October 2017 - 30 September 2018)      

Highlights

  • Lars Rasmussen steps down as CEO of Coloplast A/S. The Board of Directors appoints Kristian Villumsen as new CEO of Coloplast A/S.
  • Q4 organic growth was 8%, while revenue in DKK increased by 6% to DKK 4,234m. Full-year organic growth was also at 8%, while full-year revenue in DKK increased by 6% to DKK 16,449m. Currency developments reduced revenue by 4% for the full year and by 3% in the fourth quarter.
  • Full-year organic growth rates by business area: Ostomy Care 9%, Continence Care 8%, Interventional Urology 10% and Wound & Skin Care 3%. Price pressure of up to 1% detracted from the full-year growth performance, driven in particular by the comprehensive healthcare reform implemented in Greece which has impacted all business areas.
  • Chronic care continued the positive performance in the fourth quarter, as new products such as SenSura® Mio Convex and SpeediCath® Flex continued to drive performance. SenSura® Mio Concave has now been launched and is eligible for reimbursement in ten countries. The launch continues to go well, and Coloplast’s new product segment has been well received in the market. 2018/19 will be another launch year and in Q1 Coloplast will launch the new SenSura® Mio Baby & Kids portfolio, setting a new standard for paediatric ostomy care products.
  • The Interventional Urology business delivered 10% organic growth in the fourth quarter driven by the sales and marketing investments made in the US. The Wound Care business retained its good momentum in the fourth quarter, outperforming market growth and reporting 6% organic growth driven by China and Europe.
  • As a consequence of the ambition to accelerate organic growth during the period to 2019/2020, incremental investments of up to 2% of revenue were made at the beginning of the financial year into innovation as well as sales and marketing initiatives.
  • Full-year EBIT amounted to DKK 5,091m, a 1% increase in DKK, corresponding to an EBIT margin of 31%, compared to 32% in 2016/17. However, at constant exchange rates and adjusted for the one-off revenue adjustment relating to Veterans Affairs last year, EBIT was up by 4%, equal to an EBIT margin of 31% against 33% last year. Restructuring costs of about DKK 50m were incurred in the full-year reporting period in relation to the reduction of production staff in Denmark.
  • Full-year ROIC after tax before special items was 44%.
  • The Board of Directors recommends that the shareholders attending the general meeting to be held on 5 December 2018 approve a year-end dividend of DKK 11.00 per share. This brings the dividend paid for the year to DKK 16.00 per share, as compared with DKK 15.00 per share last year.

Financial guidance for 2018/19

  • We expect organic revenue growth of ~8% at constant exchange rates. Reported growth in DKK is guidance at 8-9%.
  • We expect an EBIT margin of 30-31% at constant exchange rates and a reported EBIT margin of ~31% in DKK. The EBIT margin guidance reflects additional incremental investments of up to 2% of revenue for innovation and sales and marketing purposes.
  • Capital expenditure is expected to be DKK ~750m, and the effective tax rate is expected to be about 23%.

Attachment

logo.png

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

DSV/Exane: Anbefalingen løftes efter købstilbud på rival

17-01-2019 10:12:08
Transport- og logistikkoncernen DSV har fået løftet anbefalingen til "outperform" fra "neutral" af Exane BNP Paribas.Kursmålet lyder fortsat på 600 kr., viser data fra Bloomberg News.Onsdag kom det frem, at DSV har budt rundt regnet 26,5 mia. kr. for den schweiziske transportkoncern Panalpina, hvor bestyrelsen nu overvejer mulighederne.DSV-aktien falder 0,5 pct. til 497 kr. torsdag efter en stigni..

Aktier/tendens: Chr. Hansen i fokus efter regnskabsskuffelse

17-01-2019 08:32:35
Chr. Hansen kommer i fokus fra aktieåbningen herhjemme torsdag, efter at ingredienskoncernen fra morgenstunden har præsenteret tal for første kvartal af det forskudte regnskabsår 2018/19. Både omsætningen og indtjeningen ramte under analytikernes forventninger.Overordnet ventes markederne i Europa torsdag at åbne med en lille pil ned, efter historien om, at de amerikanske myndigheder efterforsker ..

MHI Vestas-rival sender 10 MW-mølle på markedet - NY

16-01-2019 09:26:16
MHI Vestas' største rival, Siemens Gamesa, er nu klar til at følge i hælene på det dansk-japanske selskab med en havvindmølle med en kapacitet på 10 megawatt (MW).Onsdag morgen løfter selskabet sløret for nylanceringen, som vil blive installeret som prototype i år og være klar til installation i stor stil i 2022.Med lanceringen følger Siemens Gamesa i hælene på MHI Vestas, der i september 2018 opg..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Pandora/Sydbank: Signet-tal er skidt nyt - men ingen stor overraskelse
2
Stor britisk bagerkæde har afdækket massiv svindel
3
Aktier/tendens: Chr. Hansen i fokus efter regnskabsskuffelse
4
GE rejser kæmpemølle i Holland til sommer
5
Aktier/middag: Chr. Hansen vender på en tallerken i grønt marked - NY

Relaterede aktiekurser

Coloplast B A/S 609,80 0,9% Stigning i aktiekurs

Køb- og salgssignaler

  • Trend
  • Pengemaskinen

Copyright Berlingske Media 2019  Handelsbetingelser  |  Cookiedeklaration  |  Cookie- og Privatlivspolitik  |  Ophavsret og vilkår
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
17. januar 2019 22:15:26
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20190108.3 - EUROWEB3 - 2019-01-17 22:15:26 - 2019-01-17 22:15:26 - 1 - Website: OKAY